ELIAS debuts ECI immunotherapy
by Katie Pfaff
Biotechnology company, ELIAS Animal Health, has shared results of a new therapy that activates T-cells to attack cancer. The company focuses on canine cancer treatment with immunotherapy.
The treatment, ELIAS Cancer Immunotherapy or ECI®, relies on a mechanism of action that activates patient-specific immune system cells to recognize and fight against cancer. The technology uses a vaccine made from the cancer cells from an individual canine. Once activated and injected back into the dog, the cells are designed to attack the cancer cells within the body.
Through results from a trial of dogs are expected at the end of the year, an in vitro study with T cells and cancer cells has indicated the treatment could kill cancer cells. The in vitro trial involved cells removed from dogs with osteosarcoma and successfully induced cytotoxic action.
The results come on the heels of an earlier study with companion dogs with appendicular osteosarcoma. In that study, several dogs had long term survival.
Another trial of pet canines is underway, with enrolment that began at the start of the year. More than 100 dogs have been enrolled in the US. Data is anticipated at the end of the year.
Comments
Tag
Related Articles
Copyright © 2026 - All Rights Reserved
ISSN 2768-198X
List
Add
Please enter a comment